

26 June 2024

Treatment of Breast Cancer

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) <5
- Abemaciclib + Fulvestrant 8
- Alpelisib + Fulvestrant <5
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide <5
- Aromatase Inhibitor as a single agent <5
- Atezolizumab <5
- Capecitabine as a single agent 14
- Carboplatin + Paclitaxel <5
- Eribulin as a single agent or in combination <5
- Everolimus + Exemestane <5
- Fulvestrant as a single agent 13
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) <5
- Palbociclib + Fulvestrant 7
- Parp Inhibitors (Olaparib/Talazoparib) <5
- Pembrolizumab <5
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) <5
- Ribociclib + Fulvestrant <5
- Sacituzumab Govitecan <5
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 10
- Transtuzumab deruxtecan <5
- Trastuzumab as a single agent or in combination <5
- Trastuzumab emtansine <5
- Any other active systemic anti-cancer therapy See listed below:

Abemaciclib (Breast) 18

AC (Breast) <5

Accelerated EC- P (Breast) <5

D-Carbo-Phesgo (18) (Breast) <5

Docetaxel & Cyclophosphamide (Breast) <5

Docetaxel (Breast) <5

D-Phesgo (Breast) 8

EC-50 (Breast) <5

EC-D & Herceptin (SC) (Breast) 6

EC-D (Breast) 26

EC-D-Phesgo (Breast) 14



26 June 2024

EC-PC (Breast) 14
EC-Weekly Paclitaxel (Breast) 5
EC-Wkly Paclitaxel-Phesgo (18) (Breast) <5
Enhertu (Trastuzumab Deruxtecan) (Breast) 9
Epirubicin (Breast) <5
FEC-50 (Breast) <5
FEC-D-Phesgo (Breast) 5
Goserelin(Breast) 5
Herceptin (S/C) (Breast) 8
Kadcyla (Trastuzumab Emtansine) (Breast) 11
Paclitaxel Wkly & Herceptin(Breast) 16
Palbociclib (Breast) 34
Ribociclib (Breast) 14
Tucatinib Capecitabine Trastuzumab (Breast) <5
Vinorelbine Oral (Breast) <5
Weekly Paclitaxel-Phesgo (Breast) <5
Zoledronic Acid Adjuvant 42 day (Breast) 16

Q2. If breast cancer is not treated at or within the Trust, where are patients referred? N/A

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.